Clinical trial · Interventional
A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects With Advanced Solid Tumors
NCT03312842CI-TRIAL-00058735completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CS1001 | Drug | Sugemalimab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CS1001
- interventionNames
- Drug: CS1001
Primary outcomes (2)
- measure
- To evaluate the safety and tolerability of CS1001
- timeFrame
- From first dose to 30 days after last dose of CS1001, up to 2 years
- measure
- To determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of CS1001
- timeFrame
- From first dose to 30 days after last dose of CS1001, up to 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. With advanced-stage or metastatic tumor (unresectable) and experienced progression since last anti-tumor treatment; standard therapy is not available or rejected. 2. ECOG performance status of 0 or 1. 3. Subjects must have at least one measurable lesion. 4. Patients with life expectancy ≥ 3 months. 5. Subject must have adequate organ function. 6. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for six months after last study drug administration. Exclusion Criteria: 1. Known brain metastasis or other CNS metastasis that is either symptomatic or untreated. 2. Subjects with active autoimmune diseases or history of autoimmune diseases should be excluded. 3. Patients who have received immune checkpoint proteins/antibody/medicine (including PD-1, PD-L1, etc) for treatment. 4. Known history of HIV infection. 5. Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (HBcAb) positive or Hepatitis C virus (HCV) antibody positive. 6. Patients who have serious hypersensitive reaction to monoclonal antibodies, and have history of uncontrolled allergic asthma. 7. Known history of alcoholism or drugs abuse. For more information regarding trial participation, please contact at cstonera@cstonepharma.com
References
Publications (1)
- DERIVEDGong J, Cao J, Zhang Q, Xu N, Zhao Y, Xing B, Miao Z, Wu Y, Pan H, Gao Q, Li X, Liu B, Li W, Pei Z, Xia H, Qi Q, Dai H, Shi Q, Yang J, Li J, Shen L. Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial. Cancer Immunol Immunother. 2022 Aug;71(8):1897-1908. doi: 10.1007/s00262-021-03102-3. Epub 2022 Jan 5. PMID 34984540